The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact of discrepancy in PD-L1 expression on tumor cells between 22C3 and SP142 assay on the efficacy of pembrolizumab in advanced NSCLC patients.
 
Jun Miyakoshi
No Relationships to Disclose
 
Tatsuya Yoshida
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD Oncology; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly Japan; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines; Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical; Ono Pharmaceutical (Inst); Takeda (Inst)
 
Masayuki Shirasawa
No Relationships to Disclose
 
Masahiro Torasawa
No Relationships to Disclose
 
Yuji Matsumoto
Honoraria - AMCO; AstraZeneca; Chugai Pharma; Cook Biotech; Erbe Elektromedizin; Fujifilm; Lilly; Merck; Novartis; Olympus; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Intuitive Surgical
Research Funding - Hitachi
 
Ken Masuda
No Relationships to Disclose
 
Jumpei Kashima
No Relationships to Disclose
 
Yuki Shinno
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Bayer; Gilead Sciences; Janssen; Japan Clinical Research Operations; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yusuke Okuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); Ono Pharmaceutical
 
Yasushi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Guardant Health AMEA; Kyowa Kirin International; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Guardant Health AMEA; Janssen; Kyorin; Lilly; Merck; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Kyorin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hidehito Horinouchi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca (Inst); BMKK (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kouya Shiraishi
No Relationships to Disclose
 
Takashi Kohno
Consulting or Advisory Role - Lilly Japan
Research Funding - Chugai Pharma; Sysmex
Patents, Royalties, Other Intellectual Property - Patent fee from ThermoFisher Scientific
 
Yasushi Yatabe
Consulting or Advisory Role - Amgen; Archer; AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD K.K; Takeda
Speakers' Bureau - Amgen; Archer; AstraZeneca; Chugai Pharma; MSD K.K; Novartis; Thermo Fisher Scientific
Research Funding - Konica Minolta; Merck; Thermo Fisher Scientific
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Ono Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)